GeneOne Links With WRAIR For First MERS Vaccine Trial
This article was originally published in PharmAsia News
Executive Summary
South Korea's GeneOne Life continues to make progress in the development of the world's first DNA vaccine for Middle East Respiratory Syndrome (MERS). After filing an IND with the US FDA last month for a Phase I study, it has now signed an agreement with the Walter Reed Army Institute of Research to jointly proceed with the trial at the US institute.